Pharmaceuticals Sector Outlook — September 2026
A sector outlook on Pharmaceuticals covering diversified majors, development-stage therapeutics and specialty manufacturers — for owners, management teams and boards assessing where earnings durability sits against valuation across the public peer set and the precedent transaction record.
Key figures
- 21.4x
- Premium-end P/E (CY2027E) 13 rated companies
- 7.1x
- Discount-end P/E (CY2027E) 13 rated companies
- 11.6x
- Sector median P/E (CY2027E) 13 rated companies
- 18.8x
- Balanced growth & margin P/E 2 of 12 companies
Read the report
1 / 22 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS
Executive summary
Pharmaceutical valuation in this peer set tracks confidence in earnings durability more than near-term growth: the premium end of 13 rated names prices at 21.4x versus 7.1x at the discount end, even though faster-growing names price lower, at 10.0x, than slower growers at 15.3x. Diversified majors, development-stage therapeutics and specialty manufacturers carry different operating risks, so peer selection should start with business model. Only two of twelve names with both growth and margin data clear both bars, underscoring how uncommon balanced performance is in this set.
Key findings
- Premium multiples track earnings durability more than near-term growth
- Faster-growing names price lower than slower-growing peers in this set
- Business model — major, development-stage, specialty — should set peer groups
- Only two of twelve rated names clear both growth and margin bars
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS
This cover page introduces the Pharmaceuticals sector outlook as of September 28, 2026.
We open with the sector's core finding: valuation in this peer set tracks confidence in earnings durability rather than near-term growth. Everything that follows unpacks that finding across the market map, valuation drivers, precedent transactions and strategic implications.
Everything on this page
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS Pharmaceuticals: The Premium Sits with Durability This report shows how earnings durability, business model and asset risk sit alongside valuation across the peer set. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis P / E (CY2027E) Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
This slide lists the five report sections plus appendix that the deck covers.
We've structured this report so section one — the bottom line — carries the full story on its own, then five deeper sections build the evidence behind it. If you only have five minutes, section one holds the conclusion you need. So what: you can navigate straight to the section most relevant to your decision.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line Durable Earnings Separate the Pricing Tiers 02 The Landscape One Sector Contains Three Distinct Earnings Models 03 Valuation & Situations The Premium Survives a Forward Earnings Lens 04 Precedent Transactions Precedent Transactions Reward Different Forms of Certainty 05 Strategic Implications Durability Must Be Built into the Earnings Base 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Pharmaceuticals Split into Diversified Majors, Development-Stage Therapeutics and Specialty Manufacturers
This slide summarizes the sector's three business models and the valuation gap between the premium and discount ends of the peer set.
Pharmaceuticals splits into three earnings models — diversified majors, development-stage therapeutics and specialty manufacturers — that require different valuation frames. Among the 13 rated names, the premium end trades at 21.4x versus 7.1x at the discount end, and that gap is associated with confidence in how long earnings can hold rather than headline growth. Faster-growing names actually price lower, at 10.0x, than the slower-growing group at 15.3x, pointing toward exclusivity runway and earnings quality as more relevant tests. Only two names clear both growth and margin bars, priced at 18.8x, showing balanced performance is rare in this set. So what: peer selection and valuation judgment should start with business model, not a blended sector multiple.
Everything on this page
01 · THE BOTTOM LINE Pharmaceuticals Split into Diversified Majors, Development-Stage Therapeutics and Specialty Manufacturers The full story on one page · figures on P / E (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: P / E on CY2027E consensus (13 of 21 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (13 of 21 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Top of the Pricing Range Is Associated with More Durable Earnings The premium end of the 13 names with a forward estimate is priced at 21.4x, versus 7.1x at the discount end. Because the forward P / E lens already credits forecast earnings, the remaining gap is associated with confidence in how long those earnings can hold. 2 Faster Growth Does Not Sit with the Higher-Priced Group Among the 13 names with a forward estimate, the 7 faster-growing names are priced at 10.0x, while the 6 slower-growing names are priced at 15.3x. The result points owners toward exclusivity runway, replacement capacity and earnings quality when testing market standing. 3 Business Model Comes Before Peer Selection Diversified branded pharmaceutical majors and development-stage novel therapeutics represent 38% apiece, while specialty branded and generic manufacturers represent 24%. Their different exposure to product maturity, financing needs and loss of exclusivity makes a blended sector comparison less informative. 4 Balanced Operating Performance Is Uncommon in the Measured Set Across the 12 names with growth and margin data, 2 clear both operating bars and are priced at 18.8x. Johnson & Johnson (JNJ) and AbbVie Inc. (ABBV) occupy that position, pairing growth with established profitability. 11.6x Sector median P/E CY2027E consensus · 13 rated of 21 companies 21.4x Premium end P/E vs 7.1x at the discount end top quartile (n=3) against bottom quartile (n=3) on P/E — the spread the report explains 14 Transactions with disclosed terms 31 recorded in this tier · 1 told as case studies, the full list in the appendix
- 04SECTION 02
02
This divider introduces the section covering the sector's three distinct earnings models.
One sector contains three distinct earnings models — diversified majors, development-stage therapeutics and specialty manufacturers — each needing its own valuation frame. We'll map where enterprise value sits across these groups next.
Everything on this page
SECTION 02 02 THE LANDSCAPE One Sector Contains Three Distinct Earnings Models Diversified majors, development-stage therapeutics and specialty manufacturers require different valuation frames. 02 of 06 Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
Enterprise Value Sits Across Three Different Pharmaceutical Models
This slide groups the approved companies by business segment and shows median P/E (CY2027E) per group.
We group the covered universe into three segments to show where enterprise value concentrates within this sector. Median P/E by group frames how the market prices each business model differently rather than treating pharmaceuticals as one undifferentiated pool. So what: this grouping is the lens the rest of the report uses to keep comparisons fair.
Everything on this page
02 · MARKET MAP Enterprise Value Sits Across Three Different Pharmaceutical Models 21 approved companies grouped by business segment · median P / E (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 DIVERSIFIED BRANDED PHARMACEUTICAL MAJORS 8 cos median 15.3x Johnson & Johnson (JNJ) AbbVie (ABBV) Merck & Co. (MRK) Novartis (NVS) Pfizer (PFE) Sanofi (SNY) Grifols, S.A. (GRFS) Organon & (OGN) Cash-generative portfolios are judged on earnings durability across the exclusivity cycle and the capacity to replace revenue. DEVELOPMENT-STAGE NOVEL THERAPEUTICS 8 cos median 10.5x Disc Medicine (IRON) Phathom (PHAT) Design (DSGN) Fennec (FENC) BioAge Labs (BIOA) Fortress Biotech (FBIO) LENZ Therapeutics (LENZ) Pliant (PLRX) Asset quality, regulatory progress and cash runway matter more than current earnings for much of this group. SPECIALTY BRANDED AND GENERIC MANUFACTURERS 5 cos median 10.0x Elanco Animal (ELAN) Alkermes (ALKS) Supernus (SUPN) Phibro Animal (PAHC) ANI (ANIP) Focused portfolios bring product concentration, payer execution and manufacturing economics into sharper view.
- 0602 · LANDSCAPE
Whether a Company Looks Cheap or Expensive Depends on Which Peers It Sits Beside
This slide shows segment-level P/E medians on rated names, with company detail in the appendix.
Whether a name looks cheap or expensive depends heavily on which peer group it sits beside — a diversified major and a development-stage therapeutics company aren't priced on the same basis. We show medians on rated names by segment so you can judge standing within the right comparison set. So what: use this page, not a blended average, when you position any single name against its true peers.
Everything on this page
02 · LANDSCAPE Whether a Company Looks Cheap or Expensive Depends on Which Peers It Sits Beside Segment view of the approved universe · P / E (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median P/E Names to know What they do — and why it matters Diversified branded pharmaceutical majors 8 38% 15.3x Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · +6 more Durability anchors the story. These businesses combine established earnings with recurring exposure to the patent cliff. Portfolio replacement, lifecycle management and remaining exclusivity runway frame the market view. Development-stage novel therapeutics 8 38% 10.5x Disc Medicine, Inc. (IRON) · Phathom Pharmaceuticals, Inc. (PHAT) · +6 more Asset proof comes first. Many names are still building toward repeatable earnings. Clinical evidence, regulatory timing, financing needs and the payer path therefore carry greater weight. Specialty branded and generic manufacturers 5 24% 10.0x Elanco Animal Health Incorporated (ELAN) · Alkermes plc (ALKS) · +3 more Focus sharpens execution risk. These companies concentrate value in narrower portfolios. Gross-to-net performance, formulary access, supply reliability and product concentration can materially change the earnings profile.
- 07SECTION 03
03
This divider introduces the section testing whether the sector's premium survives a forward earnings lens.
The premium survives a forward earnings lens, but the two ends of the range point to different views of earnings durability. We'll walk through valuation, drivers, situations and the open questions next.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS The Premium Survives a Forward Earnings Lens The two ends of the range point to different views of earnings durability. 03 of 06 Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
The Premium End Prices a More Durable Earnings Base
This slide ranks all 13 rated companies by P/E (CY2027E) against the sector median of 11.6x.
Sorting all 13 rated names by forward P/E shows a wide range around the sector median of 11.6x. The premium end is priced for a more durable earnings base — the market is paying up for confidence that earnings will hold, not simply for higher current growth. So what: where a name sits in this range is a read on perceived durability, and that's the question worth testing before accepting or challenging the multiple.
Everything on this page
03 · PUBLIC MARKET VALUATION The Premium End Prices a More Durable Earnings Base P / E (CY2027E) · all 13 rated companies, sorted descending · sector median 11.6x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: P / E on CY2027E consensus (13 of 21 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (13 of 21 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same P / E (CY2027E) basis. Panel commentary is a NeuraCap view. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 21.4x CORE · median 11.6x DISCOUNT · median 7.1x Sector median 11.6x WHAT SEPARATES THE TWO ENDS The gap remains forward. The premium tier is priced at 21.4x, versus 7.1x for the discount tier. A forward P / E lens already incorporates forecast earnings, so the surviving spread is associated with confidence beyond the forecast period. Portfolio shape matters. The premium end includes diversified and specialty models. The discount end includes development-stage, specialty and diversified names, showing that the sector label alone does not define standing. Durability needs operating proof. Remaining exclusivity, replacement capacity, payer access and gross-to-net discipline provide the practical tests behind confidence in future earnings.
- 0903 · VALUATION DRIVERS
Profitability Separates the Two Ends: Names Above the 30% Margin Line Carry 15.3x Against 9.9x Below It
This slide splits rated names by revenue-growth cohort and by EBITDA-margin cohort and compares median P/E across each.
Two cuts sit on this page: by revenue growth and by EBITDA margin. The margin cut is sharper — names above the 30% margin line carry 15.3x against 9.9x below it, while the growth cut runs the other way, with faster-growing names priced at 10.0x against 15.3x for slower growers. So what: margin durability, not growth speed, is the variable most associated with where a name sits in the pricing range in this set.
Everything on this page
03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 30% Margin Line Carry 15.3x Against 9.9x Below It Median P / E (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=7; slower n=6; higher-margin n=6; lower-margin n=6). Driver readings are NeuraCap views on the supplied data — association, not causation. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 P/E, median per cohort · growth split at 7% · EBITDA-margin split at 30% The Growth Split Runs Against a Simple Momentum Story On the 13 names with a forward estimate, the 7 names above the 7% growth split are priced at 10.0x, while the 6 names below it are priced at 15.3x. The observed premium therefore sits with the slower-growing group. Exclusivity Changes the Quality of Reported Growth Growth backed by remaining exclusivity, formulary access and repeatable patient demand has a different risk profile from growth facing near-term loss of exclusivity or heavy gross-to-net pressure. Replacement Capacity Matters Beyond the Forecast A forward multiple already reflects expected earnings. Pipeline depth, label expansion and lifecycle management can help distinguish a forecast that extends from one that depends on a narrow product base.
- 1003 · SITUATION MAP
Growth Momentum and Valuation Support Sit with Different Groups of Names
This slide maps rated names on P/E versus the sector median against revenue growth versus the covered median, as observations rather than recommendations.
We cut the peer set on price versus the 11.6x sector median and growth versus the covered median to map where momentum and valuation support diverge. This is a situation map, not a recommendation — it shows where the data points, not what to do about it. So what: names in each quadrant face a different question, and the next pages walk through what that question is.
Everything on this page
03 · SITUATION MAP Growth Momentum and Valuation Support Sit with Different Groups of Names Cut on P / E vs the sector median (11.6x) (rows) and revenue growth vs the covered median (7%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Growth with Premium Standing Above-median multiple · above-median revenue growth 3 names Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · Fennec Pharmaceuticals Inc. (FENC) Among the 13 names with a forward estimate, 3 sit above both the valuation and growth reference points. The position combines operating momentum with market confidence, but durability still needs to hold beyond the forecast. Premium Without Faster Growth Above-median multiple · below-median revenue growth 4 names Merck & Co., Inc. (MRK) · Novartis AG (NVS) · Elanco Animal Health Incorporated (ELAN) · +1 more Among the 13 names with a forward estimate, 4 carry above-reference valuations despite below-reference growth. Their standing is associated with factors beyond near-term expansion, including portfolio durability and earnings visibility. Growth Awaiting Recognition Below-median multiple · above-median revenue growth 4 names Supernus Pharmaceuticals, Inc. (SUPN) · Phibro Animal Health Corporation (PAHC) · ANI Pharmaceuticals, Inc. (ANIP) · +1 more Among the 13 names with a forward estimate, 4 deliver above-reference growth while trading below the valuation reference. The strategic question is whether product mix, concentration or earnings quality limits recognition. Pressure on Both Measures Below-median multiple · below-median revenue growth 2 names Pfizer Inc. (PFE) · Organon & Co. (OGN) Among the 13 names with a forward estimate, 2 sit below both reference points. Portfolio renewal, cost structure and exposure to loss of exclusivity become central operating questions.
- 1103 · GROWTH VS PROFITABILITY
Few Names Clear Both Growth and Margin, and They Do Not Sit at the Top of the Range
This slide plots companies with both growth and margin estimates across quadrants, with median P/E per quadrant.
Plotting revenue growth against EBITDA margin for the names with both estimates shows how few clear both bars — and the ones that do are priced at 18.8x, not at the top of the range. That's a signal that the market's premium is not simply rewarding companies that do everything well; durability appears to carry more weight. So what: balanced operating performance is rare here, which raises the bar for any name claiming both growth and profitability as its story.
Everything on this page
03 · GROWTH VS PROFITABILITY Few Names Clear Both Growth and Margin, and They Do Not Sit at the Top of the Range Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 12 companies with both estimates · cuts at the covered medians (7% growth, 30% margin) · median P/E per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful P/E (balanced n=2; margin-only n=4; growth-only n=4; neither n=2). Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 0% 20% 40% 60% 10% 20% 30% 40% 50% MARGIN ONLY median 12.5x BALANCED median 18.8x NEITHER median 38.3x GROWTH ONLY median 9.6x PFE OGN MRK ELAN ALKS NVS JNJ ABBV ANIP PAHC SUPN PHAT x: revenue growth (CY2027E) · y: EBITDA margin (CY2027E) HOW TO READ THIS Across the 12 names with growth and margin data, 2 clear both the 7% growth bar and the 30% margin bar. That cell is priced at 18.8x, compared with 38.3x for the 2 names below both bars. The 4 margin-only names are priced at 12.5x, while the 4 growth-only names are priced at 9.6x. Johnson & Johnson (JNJ) and AbbVie Inc. (ABBV) are the names above both bars. The neither median rests on 2 names and is lifted by ALKS at 59.0x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 6 of 12 names clear it (JNJ, ABBV, MRK, NVS, SUPN, PHAT).
- 1203 · THE AGENDA
Doubts About Growth Point to Revenue Mix; Doubts About Margin Point to Cost Structure
This slide frames the open questions on revenue mix and cost structure that the growth and margin data raise for owners and acquirers.
Doubts about growth point toward revenue mix, and doubts about margin point toward cost structure — these are questions the cohort data puts on the table, not conclusions. We frame them as an agenda for owners and acquirers to work through against their own portfolios. So what: use this checklist to test where your own name's growth or margin gap actually comes from before drawing conclusions about its valuation.
Everything on this page
03 · THE AGENDA Doubts About Growth Point to Revenue Mix; Doubts About Margin Point to Cost Structure NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Can the Earnings Base Outlast the Patent Cliff? Test portfolio concentration, remaining exclusivity and replacement capacity against the earnings expected beyond the current forecast. What changes the answer: The answer changes when a lead product approaches loss of exclusivity without replacement revenue. Can Growth Convert into Durable Profit? Examine whether growth carries repeatable net pricing, payer access and an economic path through gross-to-net pressure. What changes the answer: The answer changes when prescription momentum fails to translate into sustained net revenue and margin. Should the Portfolio Be Built or Supplemented? Compare internal pipeline timing with partnership and acquisition routes where therapeutic fit and commercial infrastructure are clear. What changes the answer: The answer changes when internal replacement timing falls behind the exclusivity schedule. Can the Cost Base Hold Through Change? Assess manufacturing utilization, supply resilience and commercial spending against the product mix expected after portfolio transitions. What changes the answer: The answer changes when volume, mix or regulatory constraints weaken fixed-cost absorption.
- 13SECTION 04
04
This divider introduces the section on precedent transactions and the certainty they reward.
Precedent transactions reward different forms of certainty, and the record spans established brands, commercial assets and manufacturing platforms. We'll walk through case studies next, then the full list in the appendix.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Reward Different Forms of Certainty The transaction record spans established brands, commercial assets and manufacturing platforms. 04 of 06 Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13
- 1404 · DEAL CASE STUDIES
Transaction Pricing Moves with Asset Type and Earnings Visibility
This slide walks through one disclosed-terms transaction as a case study, with the complete list in the appendix.
We use one of the disclosed-terms transactions as a case study to show how pricing moves with asset type and earnings visibility. Deal multiples here are LTM at announcement, not the same basis as the CY2027E public multiples elsewhere in this report, so we don't draw a spread between them. So what: the transaction record is a separate, complementary evidence base — read it for what buyers actually paid for certainty, not as a direct comparable check against public trading multiples.
Everything on this page
04 · DEAL CASE STUDIES Transaction Pricing Moves with Asset Type and Earnings Visibility 1 of 14 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 50 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate filings collapsed; duplicate precedent id); figures are shown as recorded in the filing. 17 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Oct-2022 $2.9B Sumitovant Biopharma Ltd. Sumitovant Biopharma Ltd. paired with Myovant Sciences Ltd. in an announced pharmaceutical transaction. EV / LTM revenue 0.7x EV / LTM EBITDA 8.8x WHY THE DEAL HAPPENED The transaction suggests strategic value in combining a biopharma owner with a pharmaceutical development and commercial platform. The pairing is consistent with sector buyers seeking closer ownership of product economics and execution. HOW THE TARGET WAS VALUED The disclosed value was $2.9B, with pricing at 0.7x revenue and 8.8x EBITDA. The revenue multiple sits at the low end of disclosed revenue precedents, while the EBITDA multiple is below several disclosed EBITDA outcomes in the set.
- 15SECTION 05
05
This divider introduces the section on strategic implications for earnings durability.
Durability must be built into the earnings base, and portfolio mix, exclusivity planning and commercial execution shape that agenda. We close with the specific questions this raises for owners, management teams and boards.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS Durability Must Be Built into the Earnings Base Portfolio mix, exclusivity planning and commercial execution shape the strategic agenda. 05 of 06 Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15
- 1605 · STRATEGIC IMPLICATIONS
Earnings Visibility Is Associated with Where Owners Sit in the Pricing Range
This slide frames the questions the pricing range raises for owners, management teams and boards over the next twelve months.
Earnings visibility is associated with where owners sit in the pricing range, and that association sets the agenda for the next twelve months. For owners, the priority is protecting the durable earnings base against loss of exclusivity; for management teams, it's converting demand into repeatable economics; for boards, it's matching capital to portfolio timing. So what: these aren't recommendations — they're the specific questions this data puts in front of whoever is accountable for the answer.
Everything on this page
05 · STRATEGIC IMPLICATIONS Earnings Visibility Is Associated with Where Owners Sit in the Pricing Range NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Protect the Durable Earnings Base Prioritize portfolio mix, lifecycle management and replacement capacity where loss of exclusivity can narrow the earnings runway. FOR MANAGEMENT TEAMS Turn Demand into Repeatable Economics Focus on formulary access, prior-authorization conversion, persistency and gross-to-net discipline where growth has yet to earn stronger market standing. FOR BOARDS Match Capital to Portfolio Timing Frame build-versus-buy decisions around exclusivity schedules, pipeline maturity, financing capacity and the time required to establish commercial traction.
- 17SECTION 06
06
This divider introduces the appendix covering the full universe, methodology and sources.
The full universe, methodology and sources sit behind every figure in this report. We close with the comparables detail, the valuation basis and where each underlying disclosure lives.
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17
- 1806 · PUBLIC COMPARABLES (1 OF 1)
Public Comparables on P / E (CY2027E), Grouped by Valuation Tier
This appendix lists all rated public comparables on P/E (CY2027E), grouped by valuation tier, alongside the unrated names.
This page carries all 13 rated comparables on the P/E (CY2027E) basis used throughout this report, shaded against the 11.6x sector median. Eight names in the covered universe carry no eligible multiple and are listed separately. So what: this is the full rated set behind every valuation claim in the body of the report.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on P / E (CY2027E), Grouped by Valuation Tier Teal shading marks a P/E above the sector median (11.6x); amber marks below · 13 rated companies; 8 not rated (no eligible P/E) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 13 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV P/E (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥16.3x · median 21.4x · 3 companies Alkermes plc ALKS Specialty branded and generic manufacturers $7.8B 59.0x 6% 11% 17 Johnson & Johnson JNJ Diversified branded pharmaceutical majors $688B 21.4x 7% 38% 46 Elanco Animal Health Incorporated ELAN Specialty branded and generic manufacturers $14.8B 17.6x 5% 21% 26 CORE — 9.8x–16.3x · median 11.6x · 7 companies AbbVie Inc. ABBV Diversified branded pharmaceutical majors $534B 16.3x 9% 51% 60 Merck & Co., Inc. MRK Diversified branded pharmaceutical majors $411B 15.6x 5% 47% 52 Novartis AG NVS Diversified branded pharmaceutical majors $321B 15.0x 7% 41% 48 Fennec Pharmaceuticals Inc. FENC Development-stage novel therapeutics $338M 11.6x 42% n/a n/a Supernus Pharmaceuticals, Inc. SUPN Specialty branded and generic manufacturers $2.2B 10.0x 56% 20% 76 Pfizer Inc. PFE Diversified branded pharmaceutical majors $219B 9.9x -4% 39% 35 Phibro Animal Health Corporation PAHC Specialty branded and generic manufacturers $2.2B 9.9x 12% 16% 28 DISCOUNT — <9.8x · median 7.1x · 3 companies Phathom Pharmaceuticals, Inc. PHAT Development-stage novel therapeutics $569M 9.4x 57% 29% 86 ANI Pharmaceuticals, Inc. ANIP Specialty branded and generic manufacturers $2.0B 7.1x 12% 26% 38 Organon & Co. OGN Diversified branded pharmaceutical majors $11.1B 3.8x 4% 31% 35
- 1906 · PRECEDENT TRANSACTIONS (1 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This appendix page lists precedent transactions with disclosed terms, newest first, part one of two.
Here is the newest-first list of disclosed-terms transactions behind the case study, with deal values linked to the underlying filing. Multiples shown are LTM at announcement where disclosed. So what: this is the primary source list for anyone who wants to trace a specific transaction back to its filing.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 14 transactions with disclosed terms in this tier (31 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 50 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate filings collapsed; duplicate precedent id); figures are shown as recorded in the filing. 17 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Apr-2025 KKR & Co. Inc. → Karo Pharma AB n/a 0.7x 14.0x KKR & Co. Inc. and Karo Pharma AB were announced at 0.7x revenue and 14.0x EBITDA, placing disclosed pricing alongside an established-brand target. Oct-2022 Sumitovant Biopharma Ltd. → Myovant Sciences Ltd. $2.9B 0.7x 8.8x Sumitovant Biopharma Ltd. and Myovant Sciences Ltd. show a biopharma buyer pairing with a pharmaceutical target. Jun-2022 Gurnet Point Capital / Patient Square Capital → Radius Health, Inc. n/a 3.2x n/a Gurnet Point Capital / Patient Square Capital and Radius Health, Inc. were announced at 3.2x revenue. Sep-2019 Swedish Orphan Biovitrum AB → Dova Pharmaceuticals, Inc. n/a 3.0x n/a Swedish Orphan Biovitrum AB and Dova Pharmaceuticals, Inc. were announced at 3.0x revenue. May-2019 AmpliPhi Biosciences Corporation → C3J Therapeutics, Inc. n/a 0.7x 8.8x AmpliPhi Biosciences Corporation and C3J Therapeutics, Inc. were announced with disclosed revenue and EBITDA pricing. Jan-2019 Strides Pharma Science Limited → Vensun Pharmaceuticals, Inc. n/a 1.1x n/a Strides Pharma Science Limited and Vensun Pharmaceuticals, Inc. were announced at 1.1x revenue. Jul-2018 Cambrex Corporation → Halo Pharmaceutical, Inc. n/a n/a 15.7x Cambrex Corporation and Halo Pharmaceutical, Inc. were announced at 15.7x EBITDA. Sep-2016 Horizon Therapeutics → Raptor Pharmaceuticals n/a 3.7x n/a Horizon Therapeutics and Raptor Pharmaceuticals were announced at 3.7x revenue. May-2015 AMRI Global → Prime European Therapeuticals S.p.A. n/a n/a 13.3x AMRI Global and Prime European Therapeuticals S.p.A. were announced at 13.3x EBITDA.
- 2006 · PRECEDENT TRANSACTIONS (2 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This appendix page continues the precedent transaction list with disclosed terms, newest first, part two of two.
This page completes the disclosed-terms transaction list started on the previous page, again newest first with deal values linked to the underlying filing. Multiples shown are LTM at announcement where disclosed, consistent with the first page of this list. So what: between these two pages sits the full disclosed-terms record referenced throughout the transactions section.
Everything on this page
06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 14 transactions with disclosed terms in this tier (31 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 50 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate filings collapsed; duplicate precedent id); figures are shown as recorded in the filing. 17 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Sep-2014 Consort Medical plc → Aesica Pharmaceuticals Limited n/a n/a 11.5x Oct-2011 Hellman & Friedman LLC and The Carlyle Group Inc. → Pharmaceutical Product Development, Inc. n/a n/a 10.2x Apr-2011 Merck → Inspire Pharmaceuticals n/a 3.3x n/a n/a December 2021 → Pfizer Inc n/a 0.7x 8.8x n/a Auxilium Pharmaceuticals, LLC → Actient Pharmaceuticals, LLC n/a 5.5x n/a Value shown as recorded in the filing; deal value unit unresolved, status defaulted announced.
- 2106 · METHODOLOGY
Sources, Assumptions and Data Quality
This slide documents the report's sources, assumptions and data-quality treatment.
Every figure in this report links back to the record it was taken from, and where no link exists, the appendix names the source and the basis on which it was read. This page also documents what was excluded and why, so the analysis is auditable end to end. So what: this is where to check the basis behind any number before acting on it.
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: P / E on CY2027E consensus (13 of 21 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (13 of 21 companies), so this report follows it. P / E on CY2027E is the lead convention: it is the sector-appropriate prior for Pharmaceuticals and it clears the coverage gate with 13 of 21 companies (62%). EV / Revenue is carried as a cross-check. DATA QUALITY & EXCLUSIONS 50 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 650 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (649) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 22
In This Peer Set, the Premium Sits with Confidence That Earnings Can Endure.
This closing slide restates that the premium in this peer set sits with confidence that earnings can endure.
In this peer set, the premium sits with confidence that earnings can endure — that's the single idea to carry out of this deck. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure you want to trace further.
Everything on this page
In This Peer Set, the Premium Sits with Confidence That Earnings Can Endure. NeuraCap AI — Pharmaceuticals Coverage September 2026 · Prepared by NeuraCap AI · Confidential Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22
Sources and methodology
This report covers Pharmaceuticals (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Pharmaceuticals) with market data and consensus estimates as of September 28, 2026. The company universe is the 21 listed companies whose core business is Pharmaceuticals according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AbbVie Inc. (ABBV), Alkermes plc (ALKS), ANI Pharmaceuticals, Inc. (ANIP), BioAge Labs Inc. (BIOA), Design Therapeutics, Inc. (DSGN), Elanco Animal Health Incorporated (ELAN), Fortress Biotech, Inc. (FBIO), Fennec Pharmaceuticals Inc. (FENC), Grifols, S.A. (GRFS), Disc Medicine, Inc. (IRON), Johnson & Johnson (JNJ), LENZ Therapeutics, Inc. (LENZ), Merck & Co., Inc. (MRK), Novartis AG (NVS), Organon & Co. (OGN), Phibro Animal Health Corporation (PAHC), Pfizer Inc. (PFE), Phathom Pharmaceuticals, Inc. (PHAT), Pliant Therapeutics, Inc. (PLRX), Sanofi (SNY), Supernus Pharmaceuticals, Inc. (SUPN). The market map groups them by business vertical — Diversified branded pharmaceutical majors: 8 companies (JNJ, ABBV, MRK, NVS, PFE, SNY, GRFS, OGN); Development-stage novel therapeutics: 8 companies (IRON, PHAT, DSGN, FENC, BIOA, FBIO, LENZ, PLRX); Specialty branded and generic manufacturers: 5 companies (ELAN, ALKS, SUPN, PAHC, ANIP). 13 of the 21 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Pharmaceuticals (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Pharmaceuticals) with market data and consensus estimates as of September 28, 2026. The company universe is the 21 listed companies whose core business is Pharmaceuticals according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AbbVie Inc. (ABBV), Alkermes plc (ALKS), ANI Pharmaceuticals, Inc. (ANIP), BioAge Labs Inc. (BIOA), Design Therapeutics, Inc. (DSGN), Elanco Animal Health Incorporated (ELAN), Fortress Biotech, Inc. (FBIO), Fennec Pharmaceuticals Inc. (FENC), Grifols, S.A. (GRFS), Disc Medicine, Inc. (IRON), Johnson & Johnson (JNJ), LENZ Therapeutics, Inc. (LENZ), Merck & Co., Inc. (MRK), Novartis AG (NVS), Organon & Co. (OGN), Phibro Animal Health Corporation (PAHC), Pfizer Inc. (PFE), Phathom Pharmaceuticals, Inc. (PHAT), Pliant Therapeutics, Inc. (PLRX), Sanofi (SNY), Supernus Pharmaceuticals, Inc. (SUPN). The market map groups them by business vertical — Diversified branded pharmaceutical majors: 8 companies (JNJ, ABBV, MRK, NVS, PFE, SNY, GRFS, OGN); Development-stage novel therapeutics: 8 companies (IRON, PHAT, DSGN, FENC, BIOA, FBIO, LENZ, PLRX); Specialty branded and generic manufacturers: 5 companies (ELAN, ALKS, SUPN, PAHC, ANIP). 13 of the 21 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
50 records failed a validation gate and never feed a statistic in this report (44 excluded from aggregate; 6 quarantined). Each exclusion, with its reason: ALKS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BIOA — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BIOA — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BIOA — Implied EBITDA margin -1700.2% outside the plausible band [-100%, 80%] (effect: quarantined) · BIOA — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BIOA — Implied EBITDA margin -723.8% outside the plausible band [-100%, 80%] (effect: quarantined) · BIOA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BIOA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BIOA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BIOA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DSGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DSGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DSGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DSGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ELAN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FBIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · FBIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · FBIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · FBIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FBIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FENC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FENC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · IRON — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · IRON — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · IRON — Implied EBITDA margin -8943.4% outside the plausible band [-100%, 80%] (effect: quarantined) · further items are listed in the companion tables.
Primary valuation basis and how it was chosen
Primary valuation basis: P / E on CY2027E consensus (13 of 21 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (13 of 21 companies), so this report follows it. P / E on CY2027E is the lead convention: it is the sector-appropriate prior for Pharmaceuticals and it clears the coverage gate with 13 of 21 companies (62%). EV / Revenue is carried as a cross-check. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 14 of 21 companies; EV / rEVenue: 20 of 21 companies; P/E: 13 of 21 companies. 1 company shows a non-meaningful EV / EBITDA denominator and is excluded from that statistic. 6 companies show a non-meaningful P / E denominator and are excluded from that statistic.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥16.3x, Core 9.8x–16.3x, Discount <9.8x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 11.6x = median(pe_ratio CY2027E) (13 rated companies) · 21.4x = median(pe_ratio CY2027E) within Premium tier (n=3) · 11.6x = median(pe_ratio CY2027E) within Core tier (n=7) · 7.1x = median(pe_ratio CY2027E) within Discount tier (n=3) · 10.0x = median(pe_ratio CY2027E) | growth ≥ 7% (n=7) · 15.3x = median(pe_ratio CY2027E) | growth < 7% (n=6) · 15.3x = median(pe_ratio CY2027E) | EBITDA margin ≥ 30% (n=6) · 9.9x = median(pe_ratio CY2027E) | EBITDA margin < 30% (n=6) · 42% = median Rule of 40 score (revenue growth + EBITDA margin) (n=12) · 18.8x = median(pe_ratio CY2027E) within balanced quadrant (n=2) · 12.5x = median(pe_ratio CY2027E) within marginOnly quadrant (n=4) · 9.6x = median(pe_ratio CY2027E) within growthOnly quadrant (n=4) · 38.3x = median(pe_ratio CY2027E) within neither quadrant (n=2) · 59.0x = pe_ratio CY2027E for ALKS (quadrant outlier)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Pharmaceuticals recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 31 transactions were recorded for this industry; 14 are shown. 17 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 32 × no evidence record; 14 × deal value unit unresolved; 3 × duplicate precedent id; 1 × duplicate filings collapsed. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 654 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Bi-Weekly Update · Sep 28, 2026Pharmaceuticals Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
- Sector Report · Sep 28, 2026Medical Imaging Equipment Sector Outlook — September 2026
- Bi-Weekly Update · Sep 28, 2026Neurology and CNS Therapeutics Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
- Bi-Weekly Update · Sep 28, 2026Medical Imaging Equipment Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
Want this analysis for a company in Pharmaceuticals?
Company valuation reports run the same method against a single business — public or private.